124 related articles for article (PubMed ID: 27591526)
41. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial.
Heijstek MW; Kamphuis S; Armbrust W; Swart J; Gorter S; de Vries LD; Smits GP; van Gageldonk PG; Berbers GA; Wulffraat NM
JAMA; 2013 Jun; 309(23):2449-56. PubMed ID: 23780457
[TBL] [Abstract][Full Text] [Related]
42. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
[TBL] [Abstract][Full Text] [Related]
43. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
[TBL] [Abstract][Full Text] [Related]
44. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
45. Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection.
Díaz-Ortega JL; Bennett JV; Castañeda-Desales D; Quintanilla DM; Martínez D; de Castro JF
Vaccine; 2014 Jun; 32(29):3680-6. PubMed ID: 24837512
[TBL] [Abstract][Full Text] [Related]
46. Effect of lead exposure from electronic waste on haemoglobin synthesis in children.
Wang H; Huang P; Zhang R; Feng X; Tang Q; Liu S; Wen F; Zeng L; Liu Y; Wang T; Ma L
Int Arch Occup Environ Health; 2021 Jul; 94(5):911-918. PubMed ID: 33474627
[TBL] [Abstract][Full Text] [Related]
47. Assessment of immune response following immunization with DTP/Td and MMR vaccines in children treated for acute lymphoblastic leukemia.
Koochakzadeh L; Khosravi MH; Pourakbari B; Hosseinverdi S; Aghamohammadi A; Rezaei N
Pediatr Hematol Oncol; 2014 Oct; 31(7):656-63. PubMed ID: 25007393
[TBL] [Abstract][Full Text] [Related]
48. [Seroprevalence of antibodies against measles, rubella, mumps and varicella among school children in Madrid].
Gil Miguel A; Astasio Arbiza P; Ortega Molina P; Domínguez Rojas V; González López A
An Esp Pediatr; 1999 May; 50(5):459-62. PubMed ID: 10394183
[TBL] [Abstract][Full Text] [Related]
49. Seroprevalence of Measles, Mumps, and Rubella Antibodies in College Students in Mumbai, India.
Gohil DJ; Kothari ST; Chaudhari AB; Gunale BK; Kulkarni PS; Deshmukh RA; Chowdhary AS
Viral Immunol; 2016 Apr; 29(3):159-63. PubMed ID: 26910764
[TBL] [Abstract][Full Text] [Related]
50. Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in children.
He H; Chen E; Chen H; Wang Z; Li Q; Yan R; Guo J; Zhou Y; Pan J; Xie S
Vaccine; 2014 Jun; 32(31):4001-5. PubMed ID: 24837773
[TBL] [Abstract][Full Text] [Related]
51. The combination measles, mumps, rubella and varicella vaccine in healthy children.
Arbeter AM; Baker L; Starr SE; Plotkin SA
Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
[TBL] [Abstract][Full Text] [Related]
52. Combination measles, mumps, rubella and varicella vaccine.
Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
[TBL] [Abstract][Full Text] [Related]
53. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.
Durando P; Esposito S; Bona G; Cuccia M; Desole MG; Ferrera G; Gabutti G; Pellegrino A; Salvini F; Henry O; Povey M; Marchetti F
Vaccine; 2016 Aug; 34(36):4278-84. PubMed ID: 27423382
[TBL] [Abstract][Full Text] [Related]
54. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS;
MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231
[TBL] [Abstract][Full Text] [Related]
55. Sero-response to measles-mumps-rubella vaccine campaign in Saudi Arabia.
Al-Mazrou YY; Khalil MK; Tumsah S; Al-Ghamdi YS; Al-Jeffri MH; Tischer AB; Mishkhas AA; Eissa M
Saudi Med J; 2002 Jun; 23(6):680-3. PubMed ID: 12070547
[TBL] [Abstract][Full Text] [Related]
56. Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children.
Rager-Zisman B; Bazarsky E; Skibin A; Tam G; Chamney S; Belmaker I; Shai I; Kordysh E; Griffin DE
Clin Diagn Lab Immunol; 2004 Sep; 11(5):913-8. PubMed ID: 15358652
[TBL] [Abstract][Full Text] [Related]
57. [Sero-epidemiologic study of measles, rubella and mumps in the infantile population of Salamanca].
Sáenz González MC; Núñez Mateos JC; Rodrigo Sánchez N; Martín Sánchez AM
An Esp Pediatr; 1992 Apr; 36(4):293-7. PubMed ID: 1605414
[TBL] [Abstract][Full Text] [Related]
58. Measles, mumps and rubella infections and atopic disorders in MMR-unvaccinated and MMR-vaccinated children.
Bernsen RM; van der Wouden JC
Pediatr Allergy Immunol; 2008 Sep; 19(6):544-51. PubMed ID: 18266826
[TBL] [Abstract][Full Text] [Related]
59. Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults.
Kakoulidou M; Ingelman-Sundberg H; Johansson E; Cagigi A; Farouk SE; Nilsson A; Johansen K
Vaccine; 2013 Jan; 31(4):711-7. PubMed ID: 23174196
[TBL] [Abstract][Full Text] [Related]
60. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.
Yadav S; Thukral R; Chakarvarti A
Indian J Med Res; 2003 Nov; 118():183-6. PubMed ID: 14723482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
